PCSK9: from molecular biology to clinical applications
| Autor: | Simon W Walker, Arun Parajuli, Jonathan Malo |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Serine protease
biology Chemistry PCSK9 Clinical Biochemistry Cholesterol LDL General Medicine 030204 cardiovascular system & hematology Antibodies Monoclonal Humanized Hyperlipoproteinemia Type II 03 medical and health sciences Proprotein Convertase Subtilisin/Kexin 9 0302 clinical medicine Biochemistry biology.protein Humans lipids (amino acids peptides and proteins) 030212 general & internal medicine Proprotein Convertase 9 Lipoprotein |
| Zdroj: | Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. 57:7-25 |
| ISSN: | 1758-1001 0004-5632 |
| DOI: | 10.1177/0004563219864379 |
| Popis: | Proprotein convertase subtilisin kexin 9 (PCSK9) is a serine protease with a key role in regulating plasma low-density lipoprotein (LDL) concentration. Since its discovery via parallel molecular biology and clinical genetics studies in 2003, work to characterize PCSK9 has shed new light on the life-cycle of the low-density lipoprotein receptor and the molecular basis of familial hypercholesterolaemia. These discoveries have also led to the advent of the PCSK9 inhibitors, a new generation of low-density lipoprotein cholesterol (LDL-C) lowering drugs. Clinical trials have shown these agents to be both safe and capable of unprecedented reductions in LDL-C, and it is hoped they may herald a new era of cardiovascular disease prevention. As such, the still evolving PCSK9 story serves as a particularly successful example of translational medicine. This review provides a summary of the principal PCSK9 research findings, which underpin our current understanding of its function and clinical relevance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|